NEW YORK, Sept. 6 /PRNewswire/ -- Philip Young, Chief Executive Officer of Osteologix, Inc. (OTC Bulletin Board: OLGX) (http://www.osteologix.com) will be featured in an exclusive interview with http://www.wallst.net that is scheduled to take place on September 6 at 11 a.m. EDT. The interview will be posted on http://www.wallst.net by 8 p.m. EDT on September 6.
The interview will cover topics including Osteologix's market potential, growth initiatives, competitive positioning, recent news, and milestones for which investors should watch.
To hear the interview in its entirety, visit http://www.wallst.net, and click on "Interviews." The interview can be accessed either by locating the company's ticker symbol under the appropriate exchange at the top of the "Interviews" section of the site, or by entering the company's ticker symbol in the Search Archive window on the right-hand column of the "Interviews" section once it is posted.
Osteologix develops pharmaceutical products for bone and cartilage
disorders addressing large markets and offering low-risk development. The
therapies developed by Osteologix represent valuable solutions to the
patients suffering from diseases of bone and cartilage, and they represent
cost-effective therapeutic options for the healthcare providers. Osteologix
is developing NB S101, a once daily tablet containing strontium malonate,
as a treatment for osteoporosis. The phase II study evaluating NB S101 is a
randomized, double-blind, placebo-controlled, parallel-group efficacy and
safety trial with the objective of assessing the effects of NB S101 on bone
metabolism while also evaluating its safety, tolerability and
pharmacokinetics in postmenopausal women. In addition to the primary
|SOURCE Financial Filings Corp.|
Copyright©2007 PR Newswire.
All rights reserved